Page last updated: 2024-09-04

tipifarnib and Electrolytes

tipifarnib has been researched along with Electrolytes in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Adjei, AA; Alberts, SR; Atherton, P; Bruzek, LM; Croghan, GA; Erlichman, C; Goldberg, RM; Hanson, LJ; Kaufmann, SH; Marks, RS; Palmer, PA; Pitot, HC; Reid, JM; Sloan, JA; Thibault, A	1

Trials

1 trial(s) available for tipifarnib and Electrolytes

Article	Year
A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:7 Topics: Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Electrolytes; Enzyme Inhibitors; Farnesyltranstransferase; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Maximum Tolerated Dose; Middle Aged; Mouth Mucosa; Neoplasms; Quinolones; Time Factors	2003

Article

Year

A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:7

Topics: Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Electrolytes; Enzyme Inhibitors; Farnesyltranstransferase; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Maximum Tolerated Dose; Middle Aged; Mouth Mucosa; Neoplasms; Quinolones; Time Factors

2003